News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alcobra (ADHD) Announces FDA Clearance Of IND For Metadoxine Extended Release (MDX)



3/6/2014 9:22:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, March 6, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX) to treat cognitive dysfunctions, such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced today that the US. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for MDX. This step will allow for the initiation of US clinical trials.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES